Overview

• The new facility will locally produce active pharmaceutical ingredients critical for current and future neuroscience, immunology and oncology treatments.
• Construction is scheduled to start this autumn with full operations slated by 2027.
• This project follows AbbVie’s announced commitment of more than $10 billion for U.S. capital investments over the next decade.
• Under an Illinois EDGE agreement, the company has agreed to create at least 50 new full-time positions within three years.
• The expansion enhances a U.S. manufacturing network that already supports over 6,000 jobs across 11 sites and bolsters Illinois’ biomanufacturing ecosystem.